Why carry out this study?
|
Antimuscarinics are the front-line pharmacotherapy for overactive bladder (OAB), but there is a paucity of data on treatment persistence in this setting. |
The objective of the present study was to examine treatment patterns and to assess the medication discontinuation among different antimuscarinics in long-term nursing home (LTNH) residents with OAB. |
What was learned from the study?
|
A low proportion of LTNH residents with OAB under the fee-for-service Medicare plan is prescribed antimuscarinics. |
Antimuscarinic discontinuation during nursing home stay was high among LTNH residents with OAB. |
Discontinuation varied based on the index antimuscarinic agent, with the lowest risk of discontinuation among LTNH residents who were prescribed solifenacin and fesoterodin. |
Introduction
Methods
Data Source
Study Design and Population
Outcome Measures
Conceptual Framework
Statistical Analysis
Results
Study Population
Characteristic | Total (11,012) | Discontinued (7,319, 66.46%) | Not discontinued (3,693, 33.54%) | P value | |||
---|---|---|---|---|---|---|---|
n | Percent (%) | n | Percent (%) | n | Percent (%) | ||
Predisposing factors | |||||||
Age (mean ± SD) | 81.57 | ± 8.52 | 81.5 | ± 8.49 | 81.7 | ± 8.56 | 0.313 |
65–75 years | 2621 | 23.80% | 1764 | 24.10% | 857 | 23.21% | 0.568 |
75–85 years | 3875 | 35.19% | 2570 | 35.11% | 1305 | 35.34% | |
≥ 85 years | 4516 | 41.01% | 2985 | 40.78% | 1531 | 41.46% | |
Gender | |||||||
Male | 2799 | 25.42% | 1877 | 25.65% | 922 | 24.97% | 0.44 |
Female | 8213 | 74.58% | 5442 | 74.35% | 2771 | 75.03% | |
Race/ethnicity | |||||||
Non-Hispanic White | 9891 | 89.82% | 6540 | 89.36% | 3351 | 90.74% | 0.139 |
Non-Hispanic Black | 734 | 6.67% | 514 | 7.02% | 220 | 5.96% | |
Hispanics | 123 | 1.12% | 83 | 1.13% | 40 | 1.08% | |
Others | 264 | 2.40% | 182 | 2.49% | 82 | 2.22% | |
Marital status | 0.82 | ||||||
Unmarried (single/widowed) | 8415 | 76.42% | 5580 | 76.24% | 2,835 | 76.77% | |
Married | 2529 | 22.97% | 1694 | 23.15% | 835 | 22.61% | |
Others | 68 | 0.62% | 45 | 0.61% | 23 | 0.62% | |
Enabling factors | |||||||
Medicare/Medicaid dual eligible | 5077 | 46.10% | 3462 | 47.30% | 1615 | 43.73% | 0.004 |
Region | 0.39 | ||||||
South | 4123 | 37.44% | 2778 | 37.96% | 1345 | 36.42% | |
Northeast | 2057 | 18.68% | 1369 | 18.70% | 688 | 18.63% | |
Midwest | 3688 | 33.49% | 2420 | 33.06% | 1268 | 34.34% | |
West | 1144 | 10.39% | 752 | 10.27% | 392 | 10.61% | |
Urban–rural | 0.377 | ||||||
Rural | 3283 | 29.81% | 2,162 | 29.54% | 1121 | 30.35% | |
Urban | 7729 | 70.19% | 5157 | 70.46% | 2572 | 69.65% | |
Need factors | |||||||
Index antimuscarinic prescription¥ | < 0.0001 | ||||||
Solifenacin | 1353 | 12.29% | 809 | 11.05% | 544 | 14.73% | |
Fesoterodin | 189 | 1.72% | 116 | 1.58% | 73 | 1.98% | |
Tolterodine | 1437 | 13.05% | 1017 | 13.90% | 420 | 11.37% | |
Trospium | 243 | 2.21% | 190 | 2.60% | 53 | 1.44% | |
Darifenacin | 99 | 0.90% | 78 | 1.07% | 21 | 0.57% | |
Oxybutinine | 7691 | 69.84% | 5109 | 69.80% | 2582 | 69.92% | |
Elixhauser comorbidities | |||||||
Elixhauser Index Score (mean ± SD) | 10.12 | ± 8.77 | 9.8 | ± 8.67 | 10.7 | ± 8.95 | < 0.0001 |
Prior history of falls | 2858 | 25.95% | 1833 | 25.04% | 1025 | 27.76% | 0.003 |
Congestive heart failure | 3171 | 28.80% | 2040 | 27.87% | 1131 | 30.63% | 0.0001 |
Cardiac arrhythmias | 4477 | 40.66% | 2,882 | 39.38% | 1595 | 43.19% | < 0.0001 |
Valvular disease | 1715 | 15.57% | 1068 | 14.59% | 647 | 17.52% | 0.001 |
Pulmonary circulation disorders | 683 | 6.20% | 414 | 5.66% | 269 | 7.28% | 0.407 |
Peripheral vascular disorders | 2747 | 24.95% | 1808 | 24.70% | 939 | 25.43% | 0.788 |
Hypertension | 8851 | 80.38% | 5888 | 80.45% | 2963 | 80.23% | 0.732 |
Paralysis | 635 | 5.77% | 426 | 5.82% | 209 | 5.66% | 0.568 |
Other neurologic disorders | 2780 | 25.25% | 1860 | 25.41% | 920 | 24.91% | 0.248 |
Chronic pulmonary disease | 3404 | 30.91% | 2236 | 30.55% | 1168 | 31.63% | 0.469 |
Diabetes | 4137 | 37.57% | 2767 | 37.81% | 1370 | 37.10% | 0.615 |
Hypothyroidism | 2643 | 24.00% | 1746 | 23.86% | 897 | 24.29% | 0.195 |
Renal failure | 2031 | 18.44% | 1325 | 18.10% | 706 | 19.12% | 0.003 |
Liver disease | 357 | 3.24% | 211 | 2.88% | 146 | 3.95% | 0.505 |
Peptic ulcer | 164 | 1.49% | 105 | 1.43% | 59 | 1.60% | 0.127 |
AIDS/HIV | 14 | 0.13% | *** | *** | *** | *** | 0.58 |
Lymphoma | 91 | 0.83% | 58 | 0.79% | 33 | 0.89% | 0.0002 |
Metastatic cancer | 163 | 1.48% | 86 | 1.18% | 77 | 2.09% | 0.141 |
Solid tumor without metastasis | 782 | 7.10% | 501 | 6.85% | 281 | 7.61% | 0.576 |
Rheumatoid arthritis | 622 | 5.65% | 407 | 5.56% | 215 | 5.82% | 0.339 |
Coagulopathy | 510 | 4.63% | 329 | 4.50% | 181 | 4.90% | 0.943 |
Obesity | 847 | 7.69% | 562 | 7.68% | 285 | 7.72% | 0.214 |
Weight loss | 962 | 8.74% | 622 | 8.50% | 340 | 9.21% | 0.102 |
Fluid and electrolyte disorders | 3682 | 33.44% | 2,409 | 32.91% | 1273 | 34.47% | 0.937 |
Blood loss anemias | 222 | 2.02% | 147 | 2.01% | 75 | 2.03% | 0.299 |
Deficiency anemias | 1020 | 9.26% | 663 | 9.06% | 357 | 9.67% | 0.349 |
Alcohol abuse | 185 | 1.68% | 117 | 1.60% | 68 | 1.84% | 0.953 |
Drug abuse | 189 | 1.72% | 126 | 1.72% | 63 | 1.71% | 0.266 |
Psychoses | 1905 | 17.30% | 1287 | 17.58% | 618 | 16.73% | 0.005 |
Depression | 3171 | 28.80% | 2171 | 29.66% | 1000 | 27.08% | 0.018 |
Medication use | |||||||
Alpha-blockers | 228 | 2.07% | 155 | 2.12% | 73 | 1.98% | 0.624 |
Beta-blockers | 4564 | 41.45% | 3030 | 41.40% | 1534 | 41.54% | 0.889 |
Calcium channel blockers | 2984 | 27.10% | 2034 | 27.79% | 950 | 25.72% | 0.021 |
ACE inhibitors | 2985 | 27.11% | 1991 | 27.20% | 994 | 26.92% | 0.749 |
Diuretics | 3996 | 36.29% | 2632 | 35.96% | 1364 | 36.93% | 0.316 |
Antidepressants | 5219 | 47.39% | 3543 | 48.41% | 1676 | 45.38% | 0.003 |
Antipsychotics | 1716 | 15.58% | 1,170 | 15.99% | 546 | 14.78% | 0.101 |
Anticonvulsants | 2742 | 24.90% | 1,884 | 25.74% | 858 | 23.23% | 0.004 |
Antiparkinson agents | 1130 | 10.26% | 759 | 10.37% | 371 | 10.05% | 0.597 |
ACB scale (mean ± SD) | 0.65 | ± 1.35 | 0.72 | ± 1.42 | 0.53 | ± 1.18 | < 0.0001 |
Body mass index* | 0.426 | ||||||
Underweight | 2878 | 26.14% | 1940 | 26.51% | 938 | 25.40% | |
Normal weight | 482 | 4.38% | 323 | 4.41% | 159 | 4.31% | |
Overweight | 2385 | 21.66% | 1600 | 21.86% | 785 | 21.26% | |
Obese | 2686 | 24.39% | 1750 | 23.91% | 936 | 25.35% | |
Missing/unknown | 2581 | 23.44% | 1706 | 23.31% | 875 | 23.69% | |
Urinary continence*† | < 0.0001 | ||||||
Always continent | 1835 | 16.66% | 1153 | 15.75% | 682 | 18.47% | |
Occasionally incontinent | 1932 | 17.54% | 1216 | 16.61% | 716 | 19.39% | |
Frequently incontinent | 2583 | 23.46% | 1755 | 23.98% | 828 | 22.42% | |
Always incontinent | 1,241 | 11.27% | 941 | 12.86% | 300 | 8.12% | |
Not rated | 975 | 8.85% | 644 | 8.80% | 331 | 8.96% | |
Missing/unknown | 2446 | 22.21% | 1610 | 22.00% | 836 | 22.64% | |
Bladder continence management* | |||||||
Indwelling/external catheter | 0.663 | ||||||
Yes | 1068 | 9.70% | 703 | 9.61% | 365 | 9.88% | |
No | 7514 | 68.23% | 5015 | 68.52% | 2499 | 67.67% | |
Missing/unknown | 2430 | 22.07% | 1601 | 21.87% | 829 | 22.45% | |
Ostomy | 0.321 | ||||||
Yes | 210 | 1.91% | 149 | 2.04% | 61 | 1.65% | |
No | 8372 | 76.03% | 5569 | 76.09% | 2803 | 75.90% | |
Missing/unknown | 2,430 | 22.07% | 1601 | 21.87% | 829 | 22.45% | |
Intermittent catheterization | 0.327 | ||||||
Yes | 34 | 0.31% | 19 | 0.26% | 15 | 0.41% | |
No | 8548 | 77.62% | 5699 | 77.87% | 2,849 | 77.15% | |
Missing/unknown | 2430 | 22.07% | 1601 | 21.87% | 829 | 22.45% | |
None of the above bladder appliance | 0.766 | ||||||
Yes | 7359 | 66.83% | 4907 | 67.04% | 2452 | 66.40% | |
No | 1223 | 11.11% | 811 | 11.08% | 412 | 11.16% | |
Missing/unknown | 2430 | 22.07% | 1601 | 21.87% | 829 | 22.45% | |
Urinary toileting program* | < 0.0001 | ||||||
Yes | 1115 | 10.13% | 795 | 10.86% | 320 | 8.67% | |
No | 6020 | 54.67% | 4170 | 56.97% | 1850 | 50.09% | |
Missing/unknown | 3877 | 35.21% | 2354 | 32.16% | 1,523 | 41.24% | |
Response to toileting program* | 0.096 | ||||||
No improvement | 151 | 1.37% | 111 | 1.52% | 40 | 1.08% | |
Decreased wetness | 81 | 0.74% | 61 | 0.83% | 20 | 0.54% | |
Completely dry (continent) | 39 | 0.35% | 26 | 0.36% | 13 | 0.35% | |
Missing/unknown | 10,741 | 97.54% | 7121 | 97.29% | 3620 | 98.02% | |
Current toileting program or trial* | 0.002 | ||||||
Yes | 751 | 6.82% | 528 | 7.21% | 223 | 6.04% | |
No | 515 | 4.68% | 368 | 5.03% | 147 | 3.98% | |
Missing/unknown | 9746 | 88.50% | 6423 | 87.76% | 3323 | 89.98% | |
Bowel continence* | < 0.0001 | ||||||
Always continent | 4090 | 37.14% | 2574 | 35.17% | 1516 | 41.05% | |
Occasionally incontinent | 1216 | 11.04% | 792 | 10.82% | 424 | 11.48% | |
Frequently incontinent | 1638 | 14.87% | 1158 | 15.82% | 480 | 13.00% | |
Always incontinent | 1416 | 12.86% | 1046 | 14.29% | 370 | 10.02% | |
Not rated | 206 | 1.87% | 138 | 1.89% | 68 | 1.84% | |
Missing/unknown | 2446 | 22.21% | 1611 | 22.01% | 835 | 22.61% | |
MDS Cognition Scale* | < 0.0001 | ||||||
Intact | 9724 | 88.30% | 6391 | 87.32% | 3333 | 90.25% | |
Mild | 146 | 1.33% | 93 | 1.27% | 53 | 1.44% | |
Moderate | 370 | 3.36% | 241 | 3.29% | 129 | 3.49% | |
Moderate/severe | 93 | 0.84% | 69 | 0.94% | 24 | 0.65% | |
Severe | 395 | 3.59% | 311 | 4.25% | 84 | 2.27% | |
Missing/unknown | 284 | 2.58% | 214 | 2.92% | 70 | 1.90% | |
Activities of daily living* | < 0.0001 | ||||||
Independent | 2708 | 24.59% | 1578 | 21.56% | 1130 | 30.60% | |
Limited/extensive assistance | 379 | 3.44% | 258 | 3.53% | 121 | 3.28% | |
Dependent | 5624 | 51.07% | 3981 | 54.39% | 1643 | 44.49% | |
Missing/unknown | 2301 | 20.90% | 1502 | 20.52% | 799 | 21.64% | |
Depressed mood indicator* | < 0.0001 | ||||||
Yes | 245 | 2.22% | 182 | 2.49% | 63 | 1.71% | |
No | 7637 | 69.35% | 5,135 | 70.16% | 2,502 | 67.75% | |
Missing/unknown | 3130 | 28.42% | 2002 | 27.35% | 1128 | 30.54% |
OAB Treatment and Antimuscarinic Discontinuation
Antimuscarinic utilization rate | Antimuscarinic discontinuation rate | Time to discontinuation of index antimuscarinic medication | ||||
---|---|---|---|---|---|---|
n | Percent (%) | n | Percent (%) | Mean (SD) | Median (IQR) | |
Total | 11,012 | 100.00% | 7319 | 66.46% | ||
Index antimuscarinic medication | ||||||
Oxybutinine | 7691 | 69.8 | 5109 | 66.4 | 96.98 (102.19) | 61 (31–121) |
Tolterodine | 1437 | 13.0 | 1017 | 70.8 | 97.85 (104.01) | 61 (31–113) |
Solifenacin | 1353 | 12.3 | 809 | 59.8 | 121.82 (124.42) | 71 (43–147) |
Trospium | 243 | 2.2 | 190 | 78.2 | 80.64 (97.08) | 46 (31–91) |
Fesoterodin | 189 | 1.7 | 116 | 61.4 | 122.39 (121.58) | 75 (43–151) |
Darifenacin | 99 | 0.9 | 78 | 78.8 | 100.59 (111.14) | 59 (32–114) |
Characteristic | Adjusted hazards ratio (95% CI) | P value |
---|---|---|
Predisposing factors | ||
Age (mean ± SD) | ||
65–75 years | Reference | |
75–85 years | 0.96 (0.90–1.02) | 0.176 |
≥ 85 years | 0.97 (0.90–1.04) | 0.391 |
Gender | ||
Male | Reference | |
Female | 0.95 (0.89–1.00) | 0.070 |
Race/ethnicity | ||
Non-Hispanic White | Reference | |
Non-Hispanic Black | 1.05 (0.95–1.15) | 0.346 |
Hispanics | 0.99 (0.79–1.23) | 0.906 |
Others | 1.04 (0.89–1.21) | 0.632 |
Marital status | ||
Unmarried (single/widowed) | ||
Married | 1.04 (0.98–1.10) | 0.214 |
Others | 1.03 (0.76–1.38) | 0.867 |
Enabling factors | ||
Medicare/Medicaid dual eligible | 0.98 (0.93–1.03) | 0.460 |
Region | ||
South | Reference | |
Northeast | 0.98 (0.91–1.05) | 0.509 |
Midwest | 1.02 (0.96–1.08) | 0.558 |
West | 1.05 (0.96–1.14) | 0.271 |
Urban-rural | ||
Rural | Reference | |
Urban | 1.03 (0.98–1.09) | 0.258 |
Need factors | ||
Index antimuscarinic prescription¥ | ||
Solifenacin | 0.79 (0.73–0.85) | < 0.0001 |
Fesoterodine | 0.82 (0.68–0.99) | 0.039 |
Tolterodine | 1.11 (1.03–1.18) | 0.004 |
Trospium | 1.44 (1.24–1.66) | < 0.0001 |
Darifenacin | 1.33 (1.06–1.67) | 0.012 |
Oxybutinin | Reference | |
Elixhauser comorbidities | ||
Elixhauser Index score (mean ± SD) | ||
Prior history of falls | 0.95 (0.90–1.00) | 0.050 |
Congestive heart failure | 0.98 (0.93–1.04) | 0.518 |
Cardiac arrhythmias | 0.96 (0.92–1.01) | 0.141 |
Valvular disease | 0.95 (0.89–1.02) | 0.135 |
Pulmonary circulation disorders | 0.92 (0.83–1.02) | 0.124 |
Peripheral vascular disorders | 0.97 (0.92–1.02) | 0.248 |
Hypertension | 1.00 (0.94–1.06) | 0.888 |
Paralysis | 1.01 (0.91–1.11) | 0.908 |
Other neurologic disorders | 1.00 (0.94–1.06) | 0.979 |
Chronic pulmonary disease | 1.01 (0.95–1.06) | 0.829 |
Diabetes | 1.01 (0.96–1.06) | 0.833 |
Hypothyroidism | 0.99 (0.93–1.04) | 0.650 |
Renal failure | 1.01 (0.95–1.08) | 0.653 |
Liver disease | 0.82 (0.71–0.94) | 0.005 |
Peptic ulcer | 0.98 (0.81–1.20) | 0.861 |
AIDS/HIV | 1.71 (0.96–3.03) | 0.067 |
Lymphoma | 0.85 (0.66–1.11) | 0.238 |
Metastatic cancer | 0.80 (0.64–1.01) | 0.056 |
Solid tumor without metastasis | 1.03 (0.94–1.14) | 0.492 |
Rheumatoid arthritis | 1.02 (0.92–1.13) | 0.679 |
Coagulopathy | 1.03 (0.92–1.15) | 0.633 |
Obesity | 1.07 (0.98–1.18) | 0.134 |
Weight loss | 0.97 (0.89–1.06) | 0.494 |
Fluid and electrolyte disorders | 1.00 (0.95–1.05) | 0.852 |
Blood loss anemias | 1.06 (0.90–1.25) | 0.495 |
Deficiency anemias | 1.00 (0.92–1.08) | 0.924 |
Alcohol abuse | 0.97 (0.80–1.17) | 0.757 |
Drug abuse | 0.95 (0.79–1.14) | 0.567 |
Psychoses | 0.98 (0.92–1.05) | 0.606 |
Depression | 1.06 (1.00–1.12) | 0.060 |
Medication use | ||
Alpha-blockers | 1.01 (0.86–1.18) | 0.935 |
Beta-blockers | 1.00 (0.96–1.06) | 0.872 |
Calcium channel blockers | 1.06 (1.01–1.12) | 0.022 |
ACE inhibitors | 1.00 (0.95–1.05) | 0.931 |
Diuretics | 0.98 (0.93–1.03) | 0.379 |
Antidepressants | 1.00 (0.95–1.05) | 0.896 |
Antipsychotics | 0.93 (0.86–0.99) | 0.032 |
Anticonvulsants | 1.07 (1.01–1.13) | 0.016 |
Antiparkinson agents | 1.00 (0.92–1.08) | 0.945 |
ACB scale (mean ± SD) | 1.04 (1.03–1.06) | < 0.0001 |
Body mass index* | ||
Underweight | Reference | |
Normal weight | 1.04 (0.92–1.17) | 0.554 |
Overweight | 0.97 (0.90–1.03) | 0.314 |
Obese | 0.90 (0.84–0.97) | 0.006 |
Missing/unknown | 0.99 (0.82–1.21) | 0.960 |
Urinary continence*† | ||
Always continent | Reference | |
Occasionally incontinent | 0.95 (0.87–1.04) | 0.258 |
Frequently incontinent | 0.99 (0.90–1.08) | 0.800 |
Always incontinent | 1.09 (0.96–1.22) | 0.176 |
Not rated | 1.03 (0.83–1.28) | 0.809 |
Missing/unknown | 0.65 (0.28–1.51) | 0.315 |
Bladder continence management* | ||
Indwelling/external catheter | ||
Yes | Reference | |
No | 0.86 (0.59–1.24) | 0.411 |
Missing/unknown | 1.36 (0.60–3.08) | 0.455 |
Ostomy | ||
Yes | Reference | |
No | 1.46 (1.01–2.12) | 0.044 |
Missing/unknown | - | – |
Intermittent catheterization | ||
Yes | Reference | |
No | 0.68 (0.41–1.13) | 0.133 |
Missing/unknown | - | -– |
None of the above bladder appliance | ||
Yes | Reference | |
No | 0.96 (0.68–1.34) | 0.793 |
Missing/unknown | - | – |
Urinary toileting program* | ||
Yes | Reference | |
No | 0.75 (0.58–0.97) | 0.027 |
Missing/unknown | 0.76 (0.66–0.86) | < 0.0001 |
Response to toileting program* | ||
No improvement | Reference | |
Decreased wetness | 1.18 (0.86–1.63) | 0.299 |
Completely dry (continent) | 0.93 (0.60–1.43) | 0.736 |
Missing/unknown | 1.02 (0.83–1.26) | 0.829 |
Current toileting program or trial* | ||
Yes | Reference | |
No | 0.95 (0.83–1.10) | 0.510 |
Missing/unknown | 0.72 (0.56–0.91) | 0.006 |
Bowel continence* | ||
Always continent | Reference | |
Occasionally incontinent | 1.00 (0.92–1.09) | 0.988 |
Frequently incontinent | 1.09 (1.01–1.19) | 0.036 |
Always incontinent | 1.09 (0.98–1.21) | 0.125 |
Not rated | 0.78 (0.57–1.08) | 0.136 |
Missing/unknown | 1.32 (0.59–2.94) | 0.496 |
MDS cognition scale* | ||
Intact | Reference | |
Mild | 1.10 (0.89–1.36) | 0.387 |
Moderate | 1.04 (0.90–1.20) | 0.575 |
Moderate/severe | 1.02 (0.80–1.30) | 0.867 |
Severe | 1.25 (1.10–1.42) | 0.0001 |
Missing/unknown | 1.11 (0.97–1.28) | 0.132 |
Activities of daily living* | ||
Independent | Reference | |
Limited/extensive assistance | 1.14 (0.99–1.32) | 0.061 |
Dependent | 1.14 (1.05–1.23) | 0.003 |
Missing/unknown | 1.00 (0.81–1.25) | 0.965 |
Depressed mood indicator* | ||
Yes | Reference | |
No | 1.00 (0.86–1.17) | 0.964 |
Missing/unknown | 1.21 (1.05–1.39) | 0.010 |